Entrada Therapeutics Inc.
TRDA | NASDAQ
$6.64
-$0.11 (-1.63%)
At close: Sep 21, 2026, 4:00 PM ET
$6.64
$0 (0.00%)
Pre-market:
Sep 22, 2026, 7:59 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 25.42M | 210.78M | 129.01M | n/a | n/a | n/a |
Cost of Revenue | 4.1M | n/a | n/a | n/a | n/a | 326K |
Gross Profit | 21.33M | 210.78M | 129.01M | n/a | n/a | -326K |
Operating Income | -156M | 47.01M | -3.16M | -97.25M | -51.13M | -26.67M |
Interest Income | n/a | 19.47M | 15.22M | 2.63M | n/a | n/a |
Pretax Income | -142.83M | 66.49M | 12.06M | -94.62M | -51.16M | -26.52M |
Net Income | -143.75M | 65.63M | -6.69M | -94.62M | -51.16M | -26.52M |
Selling & General & Admin | 41.05M | 38.47M | 32.29M | 30.64M | 15.2M | 5.24M |
Research & Development | 142.27M | 125.31M | 99.88M | 66.61M | 35.93M | 21.1M |
Other Expenses | -6M | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 177.32M | 163.77M | 132.18M | 97.25M | 51.13M | 26.34M |
Interest Expense | n/a | n/a | n/a | 2.63M | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 181.42M | 163.77M | 132.18M | 97.25M | 51.13M | 26.67M |
Income Tax Expense | 924K | 859K | 18.74M | n/a | n/a | n/a |
Shares Outstanding (Basic) | 41.37M | 37.31M | 33.05M | 31.29M | 31.22M | 31.25M |
Shares Outstanding (Diluted) | 41.37M | 39M | 33.05M | 31.29M | 31.22M | 31.25M |
EPS (Basic) | -3.47 | 1.76 | -0.20 | -2.79 | -1.60 | -0.84 |
EPS (Diluted) | -3.47 | 1.68 | -0.20 | -2.79 | -1.60 | -0.84 |
EBITDA | -142.4M | 70.26M | 14.9M | -90.09M | -50.04M | -26.2M |
EBIT | -142.83M | 66.49M | 12.06M | -91.98M | -51.16M | -26.52M |
Depreciation & Amortization | 425K | 3.77M | 2.84M | 1.9M | 1.12M | 326K |
Add to Watchlist
Select watchlists to add or remove TRDA